Published in Rheumatol Int on June 05, 2014
Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) (2015) 0.87
Cigarette smoking and the risk of primary Sjögren's syndrome: a nested case control study. Arthritis Res Ther (2017) 0.75
Sjögren Syndrome Complicated by Mucosa-Associated Lymphoid Tissue Lymphoma and Lymphocytic Interstitial Pneumonia. Front Oncol (2015) 0.75
Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients. Biol Sex Differ (2017) 0.75
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum (1993) 7.14
Sjögren's syndrome. Proposed criteria for classification. Arthritis Rheum (1986) 6.11
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
The Copenhagen criteria for Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 3.27
The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med (2005) 3.26
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23
Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis (2005) 2.14
Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis (2011) 2.12
Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum (2004) 2.03
Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev (2006) 1.81
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum (2002) 1.59
Primary Sjögren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol (1995) 1.50
Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum (1998) 1.22
A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis (2001) 1.22
Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) (2006) 1.22
Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann Rheum Dis (2011) 1.18
Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control (1997) 1.18
Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) (2009) 1.17
Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. Semin Arthritis Rheum (1996) 1.15
Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) (2009) 1.10
Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) (1999) 1.08
Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum (2011) 1.08
Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis (2013) 1.07
Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) (2007) 1.03
B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun (2013) 1.02
Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol (2007) 1.01
Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med (1992) 0.94
Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun (2013) 0.93
Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum (2013) 0.88
Active immunological profile is associated with systemic Sjögren's syndrome. J Clin Immunol (2011) 0.88
Lymphoma in Sjögren's syndrome. From histopathology to molecular pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1996) 0.88
Primary Sjögren's syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia. Rheumatol Int (2012) 0.86
Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum (2013) 0.84
Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care Res (Hoboken) (2013) 0.83
Early events in Sjögren's Syndrome pathogenesis: the importance of innate immunity in disease initiation. Cytokine (2014) 0.83
Clinical features distinguishing lymphoma development in primary Sjögren's Syndrome--a retrospective cohort study. Semin Arthritis Rheum (2013) 0.82
Mucosa-associated lymphoid tissue lymphoma of the salivary glands occurring in patients affected by Sjögren's syndrome: report of 6 cases. Acta Haematol (2001) 0.82
Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. J Rheumatol (1997) 0.80
Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome. Curr Immunol Rev (2013) 0.78
Utility and safety of parotid gland biopsy in Sjögren's syndrome. Acta Otolaryngol (1996) 0.78
[Prognosis of patients with primary Sjögren's syndrome]. Med Clin (Barc) (2008) 0.76
[Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture]. Med Clin (Barc) (2010) 2.11
Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) (2002) 1.37
Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) (2004) 1.08
Diagnostic accuracy of enthesis ultrasound in the diagnosis of early spondyloarthritis. Ann Rheum Dis (2010) 1.06
Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol (2009) 1.04
Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum (2010) 1.00
Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Hum Mol Genet (2012) 0.95
Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol (2004) 0.95
Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence (2013) 0.92
The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One (2013) 0.91
Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis (2011) 0.88
Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol (2002) 0.88
Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. Rheumatology (Oxford) (2013) 0.85
Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al. Arthritis Rheum (2003) 0.80
Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. Medicine (Baltimore) (2015) 0.80
Comparison of 2 referral strategies for the diagnosis of axial spondyloarthritis in Spain. The RADAR study. Reumatol Clin (2013) 0.79
Membranous lipodystrophy. Case report and review of the literature. Joint Bone Spine (2003) 0.79
Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int (2014) 0.78
Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic. Rheumatol Int (2013) 0.78
Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int (2015) 0.77
Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) (2013) 0.77
Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore) (2015) 0.76
Lasofoxifene for postmenopausal women with osteoporosis. N Engl J Med (2010) 0.75
Cyclophosphamide in scleroderma lung disease. N Engl J Med (2006) 0.75
Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). Medicine (Baltimore) (2016) 0.75
[Medium-long term treatment with infliximab and methotrexate in posterior and/or chronic uveitis refractory to conventional treatment]. Med Clin (Barc) (2006) 0.75
SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin (2013) 0.75
Mannose binding lectin polymorphisms as a disease-modulating factor in women with systemic lupus erythematosus from Canary Islands, Spain. J Rheumatol (2003) 0.75
Management of osteoporosis in primary care before and after the result of densitometry: treatments in real practice versus the recommended by guidelines. CANAL study. Reumatol Clin (2013) 0.75
Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: A systematic literature review. Medicine (Baltimore) (2017) 0.75
[Not Available]. Nutr Hosp (2016) 0.75
[One year clinical and ultrasonographic follow up of the pilot study for the referral of patients with early spondyloarthritis (ESPIDEP)]. Reumatol Clin (2011) 0.75
[Spondylodiscitis in SAPHO syndrome]. Med Clin (Barc) (2007) 0.75
[Infliximab in ankylosing spondylitis associated with chronic hepatitis B infection. Role of Lamivudine therapy]. Reumatol Clin (2008) 0.75
No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis. Clin Exp Rheumatol (2011) 0.75